Human umbilical cord Wharton’s Jelly-derived mesenchymal stem cells differentiation into nerve-like cells
Mesenchymal stem cells (MSCs), isolated from human umbilical cord Wharton’s Jelly, were capable of differentiating into nerve-like cells using Salvia miltiorrhiza or beta-mercaptoethanol. The induced MSCs not only underwent morphologic changes, but also expressed the neuron-related genes and neuronal cell markers. They may represent an alternative source of stem cells for central nervous system cell transplantation.
Stem Cell Technology for Neurodegenerative Diseases
Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. This study explains the various types of stem cells utilized in neurodegenerative disease research and details the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and spinal muscular atrophy. As this study mentions, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases.
Human mesenchymal stem cells improve the neurodegeneration of femoral nerve in a diabetic foot ulceration rats
In this study, the data suggested that human umbilical cord mesenchymal stem cell (hMSCs-UC) treatment partially reversed the neuronal degeneration and nerve function of femoral nerve (FN), which might be contributed by the upregulation of NGF with dramatic angiogenesis in FN-innervated gastrocnemius, consequently reversing neuronal structure and function, preventing or curing foot ulceration.
Stem Cells for the Treatment of Neuropathic Pain
Stem cell transplantation can effectively relieve neuropathic pain under different pathological conditions. However, it is interesting to point out that peripheral neuropathic pain seems to be more responsive to stem cell therapy than SCI (Spinal Cord Injury) induced chronic pain. Moreover, stem cell treatment does not always exert positive results in SCI-induced chronic pain (e.g. aggravating pain above the lesion spinal cord segment).
Mesenchymal Stem Cells as a Prospective Therapy for the Diabetic Foot
The diabetic foot is a serious complication of diabetes. Mesenchymal stem cells (MSCs) are an abundant source of stem cells which occupy a special position in cell therapies, and recent studies have suggested that mesenchymal stem cells can play essential roles in treatments for the diabetic foot. This study discusses the advances that have been made in mesenchymal stem cell treatments for this condition. The roles and functional mechanisms of mesenchymal stem cells in the diabetic foot are also summarized, and insights into current and future studies are presented.
Effect of subcutaneous treatment with human umbilical cord blood-derived multipotent stem cells on peripheral neuropathic pain in rats
In this study, the researches aim to determine the in vivo effect of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs) on neuropathic pain, using three, principal peripheral neuropathic pain models. They determined subcutaneous administration of hUCB-MSCs might be beneficial for improving those patients suffering from neuropathic pain by decreasing neuropathic pain activation factors, while increasing neuropathic pain inhibition factor.
Perspectives of employing mesenchymal stem cells from the Wharton’s jelly of the umbilical cord for peripheral nerve repair
Mesenchymal stem cells (MSCs) from Wharton’s jelly present high plasticity and low immunogenicity, turning them into a desirable form of cell therapy for the injured nervous system. Their isolation, expansion, and characterization have been performed from cryopreserved umbilical cord tissue. Great concern has been dedicated to the collection, preservation, and transport protocols of the umbilical cord after the parturition to the laboratory in order to obtain samples with higher number of viable MSCs without microbiological contamination.
9:00am - 7:00pm
9:00am - 6:00pm
9:00am - 7:00pm
9:00am - 5:00pm
9:00am - 5:00pm
Saturday & Sunday